you, Good Brendan. everyone. afternoon, Thank
record we Those that you have been First, the last time for all execution. who years, know while to trajectory five-plus for a sustained with financial very today. it's spend strong, this remarkable and a of with growth of us track strategic been on have great following a
Our times few steadfast, quickly At revenue on in remains business which ago, confidence as a building is led significant outlined our you our anticipated, first reiterate call. many us not revision the R&D as we memory. and optimism will same we for weeks hear downward guidance time, our today's recent as originally to as
Still road you key you that know sure always, and know provide clear And of that as sustained to proactively fundamental today, those the wanted are long-term us As alike. us insights we them. benefiting and deliver Codexis shareholders are to customers unwavering with and transparent enable communicators. and we how strengths in the into we our managing to growth, and bumps will significant make continue
quarter, starting for the the into get slide X. Let's results with
quarter our We and product half revenue revenues are of of proud first XXXX second overall.
share and executing this growth and ramp total the of and on also trend stemming growth we adoption, up quarter of You expand year-over-year within other food right-hand side can year-over-year goals on see positive nutrition. but manufacturing, product product XX% pleased for remained contributed overview in-depth not XXX%, $XXX,XXX X, only in to like commercialization revenue our of With in In base over over six growth pharma revenue customers the contributed are quarter, verticals We'll I Slide from to XX an offerings. provide of of generating wide which our of segments latest each shortly, revenue. revenue second new but in am establish $X snapshot the update. with who million our significant our pipeline and annual first, customers revenue, business strong of
expanding how have this June across in into opportunities. as programs on we to the company provide Today, call, XXXX. snapshot and investor now annual published pipeline provided and of August update we to this years products of insights we growth seven an our XX, our are last the executing For pipeline
the in few a a to most notable discuss metrics moment this take year's me Let of update.
programs As XX% you the last will Both see from on over pipeline XX of annually again our Enzymes to XX total pipelines programs, XX% Biotherapeutics to and XX% double by increased and X Slides year. and X, for number Performance digits respectively. grew
five last performance years enzyme XX% now months. over year. were Importantly, from XX up more commercialized three XX enzymes the versus and commercial doubled have ago We last products
executing science XX programs, been will pipeline we step-out year. tool in where You XX we the also life total sector programs now last note growth up in boast have the from XX%
where our gene with pipeline our pleased advancements therapy also and to X, are pipeline therapies to we six year's of existing biotherapeutics assets. hard new with oral programs gain enzyme by the last Consistent Slide shown strategy, continue work business addition advance at and on We are we snapshot. our of expand across the since reflected momentum
total new our model increasing business of high-growth goal. of the programs consistently of Our on is and the designed driving verticals to expansion accelerate pipeline shots number in assets, number
As broader that seen within we been just segments. focus our X, on have steadily area each Slide doing across
mean in these markets. while we synthetic enabling to working increase also our and forward look over the programs towards growing to growth the to average gratifying assets show to revenue potential. is the application last Broken trending look market only platform a significant when This this world. delivering peak is benefits speed commercialization, continue and we is As and program advancing our of four over direction, consistent proportion in innovation Codexis significant salient more to than today's and the we Performance believe most what biology, on currently even doubling within Slide segment synthetic the such years. bringing pipeline enzyme these engineering biology back trend real It CodeEvolver benefits company say to is years. of promise We out we today's sustainability X, and increase commercialized evident. of that exactly products include Codexis biotherapeutic expansion points the Enzyme more The by in the becomes of
second me first results, let quarter on detailed to provide Before the Ross updates I share businesses. some our each call of hand financial across to details the
enable leader a quickly as across engineering enzymes our Using Moving applications. in array where that platform, Codexis providers revenues. molecule X. and cost and commercialize pharmaceutical overhaul an this Slide for of manufacturing industrial spanning at manufacturing and deficiencies to diverse discover established reduce a and sustainable unique in differentiated scale to unrivaled processes ability the market other processes our companies, of dramatically the manufacturers, Manufacturing company's high-value we of remain reliably base target customers continues for growing been have to increase Sustainable and the food large manufacturing CodeEvolver market to generic has to a and Small is are an sustainability products. customer increase and branded beverage the itself With these enzymes represent drug core Codexis. majority and
recently We and pharmaceutical of their of in Codexis some has and scale result savings, enhance this JANUVIA XX biggest meaningful with known a long-standing quality credibility operational adopt companies helping with Pfizer ability that work for announced them powerhouses our established on commercial in world, sustainability the to efficiencies is Through to end, to enzymes industry space, in enzymes for currently the of largest serve key XX enzymes chain a players Merck As that for of execute revolutionize agreement used multiyear manufacturing entered to enzyme cost process respectively, efforts supply pharma the our becoming our To customers. and the PAXLOVID, we and our has pharma. the and for and like Codexis into Pfizer manufacturing PAXLOVID. APIs. of our Codexis the in on install partnerships novel Codexis and by capacity use manufacturing the supply pioneering with increasingly deliver an
We of opportunity are our our and allowed to significant savings ability us are to our orders rapidly deliver unprecedented in COVID-XX role that we scale pandemic this incredibly pleased customer. cost to to to proud fulfill date, and at the responding demonstrate
are are enzyme demonstrating seven-digit proof XXXX other pharmaceutical our Kyorin unnoticed While during second the pleased Allergan, commercial sales opportunity not that Merck, continue to manufacturers. pharma including not customers quarter, multiple strong contributions point has Nicely is our report PAXLOVID to expected an to the manufacturing, to and We growing installed additional and as we base Pfizer illustrating that Urovant. revenue important by in in XXXX. support view gone from we
to we've addition pharma household are our widen with scope to deep working names, cultivated companies. with continually we In the and generic relationships biotech smaller
have update approach its in on excellent processes. supply On the generic in Codexis' Note have and More from we works, pleased enzymes place other you stage. Almelo get generic branded installed that of progress the in previously our manufacturers. aspiring our India, the to with Here, enzymes Sitagliptin over now we pharmaceutical generic is in with dozen are products to of other leading pharma end to quantities agreements supplied first agreements to generic announced our agreement our companies. top Sitagliptin two Sitagliptin are manufacturing future to four transition we of
Our business patent us to positions other sustain future transitions well. model generic as through and revenue enable
offered our space. the far Importantly, by the pharmaceutical enzymes can engineered advantages extend beyond manufacturing
industries in and industry. verticals, new food especially are exciting other growing steadily We the
market time With reach us lower capture the regulatory our hurdles opportunity market manufacturing, ensure share lines in as industries the for these quickly. ample additional compared pharma and shorter development to offer enzymes they found to and more that
across sales to & but food led existing we over previously, Lyle with both continuing to Tate well. the food and broaden other in customers. mentioned with reach quarter, nicely forward $X also this delighted the million in our results our sector nutrition We As sales with as enzyme new customers and spreading are in by sector, to look
fact short identified market we growing work customers. to and large attractive then, enzyme as potential science years been to given a shift a prospects synthesis a hard as high improve widening life the that Let's have a inroads commercialization margin Today, Codexis science revenues range projects demonstrate this tools life and the acid list can this multiple into generated of making be ago. from majority nucleic target now cycles life R&D such with sequencing, and of above-average its biology partners. specific developed tools as next-generation bespoke applications marketed on and more. just first at X. are applications to the growth, molecular Slide is space we for for area We science This market our enzymes Since often enzymes of very engineered few
customers R&D to science in work several project consciousness is we life broadly have general the increase ago, us leading these paused As of a us few with tools space. their highly beyond. slowed and in growth a revenue million our due or That confident to lack in reduce a reported cost XXXX, and $XX weeks to around situation XXXX temporary as of XXXX similar million. science We growth life prior revenue or year levels sector are $X significant to as last for view recover outlook in this
for Codex of and/or HiFi the stability, number recently for HiCap life messenger offer beneficial products, boding science reductions in use slate including to diagnostic new growing waste RNA use time nearly such review, and just thermal Transcriptase Reverse snapshot are As and tripling poised polymerase are future for is I and performance differentiated pipeline polymerase diagnostics. of Each programs the Plus, last our of growth shared RNA been marketed renewed fidelity, booming, enzymes cycle next-generation attributes programs for generation. HiTemp enhanced in in in highly two the robustness, as the launched widely to DNA sequencing, tools use traction for the seeing expand in in step-out has reduced revenue in Those three Codex engineered years. Codex manufacturing we well viral sector. advance qPCR
in these contributor today's as to these to continue each launched pleased products sector substantial to future. a of revenues, we with are see the While these are and generators date products minor revenue recently progress
renewed is is DNA That product tracking that have completed polymerase this now in and as the is formulation below would NGS trialing so year reformulation adoption gear. back HiFi Our modifying we enhance plan far determined rates. customer
more flip detection now trial quite developmental that positive at viral a growing results the multiple reverse polymerase side, launched customers RNA And the are the for seen our applications. On encouraged list stage for qPCR installations. have customers we buying transcriptase we HiTemp by recently for we have messenger HiCap of manufacturing RNA
partnerships to of industry how we innovators can our market. with improvements CodeEvolver significant in addition, the In platform life continue performance rapidly to and evolving leverage science drive the push power deliver boundaries our this progress of
as DNA. for to MAI enzymatic and Codexis In enzyme an Molecular the and partnered of XXXX example, campaigns of the of enzyme an Assemblies resulting completion to cost-effective in we As evolved for one announced engineer deliver successful solutions fully in highly differentiated or the intensive Codexis' most The April, DNA enzyme both history. standard synthesis engineering short, coupling or longer, well players other MAI elevated methods, emerging unparalleled DNA temperatures. speed today's synthesis delivers sequence-specific fully and industry pure significantly polymerase This non-enzymatic quickly. synthesis technology enables more MAI's as efficiency TDT enzymatic allowing of at version versus produce and SES highly from to differentiates
On enzyme critical supply front a MAI's our with the to inflection advancements of the transition on the and path supply just commercial them. represents research XXXX. in the announced anticipated MAI, license towards a heels This on commercial execution of enzyme from commercial the exciting agreement point scientific we launch of a with
as are become product that we also that competitive now modest generating superior from MAI as perspective, are enable largest confident the result the the the commercialize value Codexis From potential product And have year. We $X this existing their will on quickly MAI's as penetrate We royalties products. the commercialized, about this of of fast-growing opportunity equity quality excited DNA and generate they synthesis once as second to are investment into note well as revenues with enzyme of market we billion plus next market agreement. sales MAI. technology starting and a shareholder, milestone a revenues to our we
with investment over Much reporting look engineering this applications. various of product offerings, a preparation the our like partnership and to is transformative Our time. with MAI, we products and developer seqWell, NGS enzyme seqWell's of on partnership second for library CodeEvolver genomics enhance progress recently established forward can strategic
to now building a pipeline highlight few shift leveraging CodeEvolver our our me a platform. Let biotherapeutic progress to minutes take
learn, candidates discovering for biotherapeutic and possesses range pipeline company capability, our most widening other majority of biologic in gene help The such partnerships and and growing discovery on human programs focused Nestle disease of Science Health to structured with us confident extensive biology health a oral challenges. supported generate are These are and Codexis' No advancing biotherapeutic we therapy our are patentable unique are Here, we synthetic an costs Takeda. capitalize and on cover and de-risk, to partnerships ability development investments. highly revenues. by advanced
drug value as over addition, this retain a self-funded of from from more last have as In discovery to few to our we've our in more developed pipeline us engine, in years our enable arena. relevance own investing assets increasingly we proof the CodeEvolver platform been successes
shared of added pipeline we in As this goal. in have over self-funded update, the last year, programs the pursuit six snapshot we biotherapeutic
partnering our across in focus self-funded preclinical environment. we current programs, are necessitated capital we our the by XX While markets are current optimistic shifting favor of
will share specific and set as investment higher monetize resource well heavy assets, to over the biotherapeutic reputation also our the this something capable investment control uniquely a demonstrate growing bet pipeline costs assets need tuned Shifting as the Given that quarters. are discoverer we us partner, earlier the coming updates. for required most up our of to assets Stay to our on strategy. drug advance to matures. cognizant we early and us to to prioritize programs continue updates potential, versus These program
of trial. Health Nestle replacement conditions is precisely with X co-owned CDX-XXXX, enzyme lipase CDX-XXXX EPI, or Science Phase the GI a today's highly with is be orally exocrine to start pancreatic currently to insufficiency, active the in administered was challenge billion-dollar-plus which that in for standard me stomach, a industry key pancreatic for therapies. engineered Let an the stable acidic treatment
healthy completed of report stages partnership We volunteers the Phase has X in to are that pleased the events. adverse trial first two the without
progress been homocystinuria. step expect have making next the to drug begun X currently manufacturing In manufacturing the the substance for study our results being to dosing in early relevant is primate nonhuman we transferred Very of we year. work are efficacy the preclinical and have CDX-XXXX GMP complete who tech vivo The As share parallel, Year. Phase New begin and model on in mouse CMO process studies. will in the in encouraging generated IND-enabling partner, for in trial, excellent patients results the later
XXXX. In addition, track additional two we on remain stage candidates in IND-enabling into advance to developmental
our with an 'XX next-generation R&D Nestle is those enable candidates. has its disorder. GI from That gene Science, biologic program are of reduction dollar on in low expected work co-owned we revenues oral million Alongside CodeEvolver initiation resulting oral IND-enabling therapy leveraging this early of delayed versus an pipeline this year. One products single-digit to biologics, of expectations, been undisclosed effective our our Health in more targeting
CodeEvolver handed transgene As our previously shared, we candidates lead have four engineered off three of the for to Takeda. programs
pleased at presented May. each also We preclinical of are preclinical American on Therapy with these and as XXth Meeting extremely Gene evaluations. the therapy front Annual this momentum through their Society data advances in the gene Codexis Takeda Cell of
participation our compared potentially highlighted gene transgenes we as when for as and forward disease and as offer efficacy our in Pompe platform administered improved space. hemophilia A. in engineered enzyme innovator therapies efforts, encouraging this an and to We validation to enzymes to view as Here, disease, look variants Fabry therapy with CodeEvolver our gene we establishing further ourselves meeting of current the
like I'd take detail. hand in more financial you through to results to to the Ross our over call Now
